Drugs / 4-hydroxytamoxifen
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04570956 | Jul 2021 → Oct 2024 | atypical lobular breast hyperplasia, lobular breast carcinoma in situ | Mayo Clinic | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00084344 | Apr 2003 → Jul 2004 | breast cancer | Northwestern University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-hydroxytamoxifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084344 ↗ |
| Known as | 4-OHT | “Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day” NCT04570956 ↗ |
| Route | Topical | “Participants apply 4-hydroxytamoxifen gel in 4 metered doses daily to each breast” NCT00084344 ↗ |